Accessibility Menu
Alpha Teknova logo

Alpha Teknova(NASDAQ) TKNO

Market Cap$284.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-79%
5 Year-75%
1 Year+25%
1 Month-8%
$5.50
+3.77%
+0.20Today
After hours$5.51+$0.01 (+0.09%)
Alpha Teknova last closing stock price
MetricPriceDate
Last closeUSD 5.302026-08-03
Alpha Teknova stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.28%USD 4.852026-07-27
1 month-8.46%USD 5.792026-07-02
3 month+41.71%USD 3.742026-05-05
Year to date+39.47%USD 3.802025-12-31
1 year+25%USD 4.242025-08-01
3 year+67.72%USD 3.162023-08-04
5 year-75.35%USD 21.502021-08-04
Since inception-78.8%USD 25.002021-06-25

Alpha Teknova Financials at a Glance

Market Cap

$284.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$41.80M

Net Income (TTM)

-$17.17M

EPS (TTM)

-$0.32

P/E Ratio

-16.53

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$5.50

Volume

157,683.335

Open

$5.33

Previous Close

$5.30

Daily Range

$5.14 - $5.80

52-Week Range

$1.91 - $6.68

Estimated Earnings Date

Aug 5, 2026

TKNO News

Foolcom-Featured.png

Alpha Teknova (TKNO) Q2 Revenue Jumps 7%

Motley Fool Markets TeamAug 7, 2025

TKNO: Motley Fool Moneyball Superscore

44

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alpha Teknova

Alpha Teknova makes critical reagents for life sciences companies. These chemical formulations help scientists develop new drugs, vaccines, and diagnostic tests. Teknova serves pharmaceutical firms, biotech companies, and research institutions.

The Lab Menu

Lab Essentials: Research-grade reagents and custom formulations for scientific research, accounting for 77% of 2024 revenue.

Clinical Solutions: Custom products supporting protein therapies, gene therapies, and mRNA vaccines, accounting for 19% of 2024 revenue.

Media Plates: Pre-poured plates that provide environments for cell growth and cloning experiments.

Cell Culture Media: Liquid formulations and supplements that nourish cells during laboratory expansion.

Molecular Tools: Specialized reagents that help scientists manipulate, resuspend, and purify biological samples.

Building the Business

Teknova has invested in manufacturing automation to increase production capacity and efficiency.

The company went public in June 2021, listing on the NASDAQ Global Market.

Teknova has expanded facilities to support growing demand for custom and GMP-grade products.

The company has positioned itself in the evolving cell and gene therapy market.

What Makes Teknova Special

Teknova delivers custom research products quickly, with 66% of custom RUO products shipped within three weeks in 2024. The company maintains strong customer relationships, with a 95% retention rate for customers spending over $10,000 annually in 2024.

Five Things You Need to Know

Teknova reported net losses of $26.7 million in 2024 and $36.8 million in 2023.

The company maintains a 95% retention rate among customers spending over $10,000 annually, who represent 15% of the customer base and generate 90% of 2024 revenue.

Two suppliers accounted for 49% of Teknova's total inventory purchases in 2024.

Teknova was founded in 1996 and is headquartered in Hollister, California.

The company employs 173 full-time workers at year-end 2024.

Bottom Line

Teknova provides essential chemical ingredients that power life sciences research and development. Despite operating losses, the company maintains strong customer loyalty while serving the growing biopharmaceutical industry.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

158

CEO

Stephen Gunstream, MBA

Website

www.teknova.com

Headquarters

Hollister, CA 95023, US

TKNO Financials

Key Financial Metrics (TTM)

Gross Margin

33.33%

Operating Margin

-39.02%

Net Income Margin

-41.07%

Return on Equity

-24.32%

Return on Capital

-20.23%

Return on Assets

-17.40%

Earnings Yield

-6.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$284.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

53.61M

Volume

157.68K

Avg. Volume

167.87K

Financials (TTM)

Gross Profit

$13.93M

Operating Income

-$16.31M

EBITDA

-$9.96M

Operating Cash Flow

-$7.70M

Capital Expenditure

-$1.16M

Free Cash Flow

-$8.87M

Cash & ST Invst.

$4.31M

Total Debt

$14.66M

Alpha Teknova Performance Analysis

Alpha Teknova annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 41,420,00012.3%
20232023-12-31USD 36,684,000-11.4%
20242024-12-31USD 37,745,0002.9%
20252025-12-31USD 40,520,0007.4%
Alpha Teknova sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-305.0%
Q32025-09-301.6%
Q42025-12-31-4.5%
Q12026-03-3110.9%
Alpha Teknova annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.69382.9%
20232023-12-31USD -1.16-31.6%
20242024-12-31USD -0.57-50.5%
20252025-12-31USD -0.32-43.6%
Alpha Teknova sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3023.1%
Q32025-09-30-19.8%
Q42025-12-31-12.5%
Q12026-03-315.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$11.08M

+13.1%

Gross Profit

$3.50M

+16.3%

Gross Margin

31.57%

N/A

Market Cap

$284.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.80M

N/A

Employees

158

N/A

Net Income

-$4.56M

+1.9%

EBITDA

-$2.71M

+6.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.31M

-83.6%

Total Debt

$14.66M

-50.1%

Accounts Receivable

$5.67M

+1.0%

Inventory

$6.87M

+4.6%

Long Term Debt

$12.74M

-53.7%

Short Term Debt

$1.92M

+3.5%

Return on Assets

-17.40%

N/A

Return on Invested Capital

-17.77%

N/A

Free Cash Flow

-$3.58M

+16.9%

Operating Cash Flow

-$3.36M

+18.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PRQRProQR Therapeutics N.V.
$1.83+7.02%
CGCCanopy Growth Corporation
$0.93-2.76%
ACBAurora Cannabis Inc.
$2.81-0.71%
LFCRLifecore Biomedical, Inc.
$4.35-0.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
AMIXAutonomix Medical
$19.04+4.22%
SPCXSpace Exploration Technologies
$125.52+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.08+0.03%

Questions About TKNO

What is the current price of Alpha Teknova?

Alpha Teknova is trading at $5.52 per share.

What is the 52-week range for Alpha Teknova?

Over the past 52 weeks, Alpha Teknova has traded between $1.91 and $6.68.

How much debt does Alpha Teknova have?

As of the most recent reporting period, Alpha Teknova reported total debt of $27.83M.

How much cash does Alpha Teknova have on hand?

Alpha Teknova reported $4.31M in cash and cash equivalents in its most recent financial results.

What is Alpha Teknova’s dividend yield?

Alpha Teknova does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services